On 2026-09-30, Barclays lowered its INSM price target to $207 from $237 (-12.7%).
Barclays 于 2026-09-30 将 INSM 目标价下调至 $207，此前为 $237，变动幅度 -12.7%。
For information only. Not investment advice.内容仅供参考，不构成投资建议。
INSM regulatory decision: FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027Insmed Incorporated（INSM）披露重大监管决定
Material Company Event · September 21, 2026公司公告 · 2026/9/21
Adsett Roger sells $32.0M of INSMAdsett Roger 内部减持 INSM $32.0M
Insider Sale · August 12, 2026内部人减持 · 2026/8/12
INSM files 8-K — Item 2.02 Results of OperationsINSM · 8-K 披露
8-K Event · May 7, 20268-K 披露 · 2026/5/7
